Exports of the vaccine continue to be a point of contention between the EU and UK, while newly released US trial results are quickly amended.
Articles on AstraZeneca vaccine
Displaying 81 - 100 of 156 articles
These results can help allay previous concerns in Europe about a lack of trial data for older people.
AstraZeneca just announced results from its US-based trial. It found the vaccine to be 79% effective and safe for use, despite recent concerns around reports of blood clots.
From today, around 1,000 clinics around the country can begin vaccinating eligible Australians.
Underlying medicines ‘do no harm’ principle is a deeper claim that it is worse to do harm than to allow harm to happen.
Supply chain issues can be addressed – but the issues with the AstraZeneca vaccine are political, too.
The European Medicines Agency has said the Oxford/AstraZeneca vaccine is not associated with an increased overall risk of developing blood clots.
It’s not too late for Australia to repair our vaccine strategy, though we will never make up for the months lost.
The government is gifting 8,000 doses of COVID-19 vaccines to Papua New Guinea for frontline health workers, and is requesting an additional 1,000,000 doses from European authorities for the pacific nation.
Suspensions of the AstraZeneca vaccine may dent confidence and will slow down coverage – arguably creating a greater risk to public health.
Blood clots form to prevent blood loss both inside and outside the body. But they can become dangerous if they get dislodged from where they form.
Injected vaccines tend to generate good immunity overall but less of a response in the nose and throat, where the virus enters and spreads from.
Data from clinical trials and the real world COVID vaccine rollout suggest blood clots occur no more frequently in vaccinated people than they do in the general population.
The European Medicines Agency has found no link between thrombosis and the AstraZeneca vaccine, but precautionary investigations are continuing in some countries.
With four COVID-19 vaccines approved for use in Canada, it’s time to answer FAQs about efficacy, immunity, eradication and variants.
Italy’s decision to block export of AstraZeneca vaccines to Australia will likely not impact our vaccine roll-out. But vaccine scarcity is a looming problem in other parts of the world.
Fears that the vaccine doesn’t work in older people appear unfounded.
Good decisions and investment have built a strong supply chain, while various experts have helped with distribution.
The global vaccine rollout has not been free from geopolitical rivalries and point-scoring.
The Oxford/AstraZeneca vaccine is the second COVID shot to be approved in Australia, and it’s likely Australians will start receiving it next month.
Top contributors
-
Professorial Fellow, University of Canberra
-
Senior Research Fellow in Global Health, University of Southampton
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Medicine, University of East Anglia
-
Professor of Health Service Operations, School of Pharmacy & Medical Sciences, University of Bradford
-
Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Distinguished Professor, Professor of Immunology, RMIT University
-
General Practitioner, PhD Candidate, Bond University
-
Professor of Immunology, RMIT University
-
Chair in Epidemiology, Deakin University
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Professor of Intellectual Property Law, Queen Mary University of London
-
Postdoctoral Research Fellow, RMIT University